- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05441761
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposomes in Combination With Gemcitabine, Dexamethasone, and Cisplatin in Relapsed/Refractory Peripheral T-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Daobin Zhou, Dr
- Phone Number: +8613901113623
- Email: Zhoudb@pumch.cn
Study Contact Backup
- Name: Chong Wei, Dr
- Phone Number: +8613521760705
- Email: QH5035@163.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Daobin Zhou, Dr
- Phone Number: +8613901113623
- Email: Zhoudb@pumch.cn
-
Contact:
- Chong Wei
- Phone Number: +8613521760705
- Email: QH5035@163.com
-
Beijing, China
- Not yet recruiting
- China-Japan Friendship Hospital
-
Contact:
- Zhenling Li, Dr
- Phone Number: +8613520114408
- Email: zryyxy2013@163.com
-
Beijing, China
- Not yet recruiting
- Beijing Hospital
-
Contact:
- Hui Liu, Dr
- Phone Number: +8613520618812
- Email: liuhui8140@126.com
-
Beijing, China
- Not yet recruiting
- Peking University First Hospital
-
Contact:
- Yujun Dong, Dr
- Phone Number: +8618210264969
- Email: dongy@hsc.pku.edu.cn
-
Beijing, China
- Not yet recruiting
- Beijing Luhe hospital, Capital Medical University
-
Contact:
- Hebing Zhou, Dr
- Phone Number: +8613681210186
- Email: zhbyffs@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects fully understand and voluntarily participate in this study and sign informed consent
- Age ≥18, ≤75 years, no gender limitation
- Expected survival ≥ 3 months;
- Histologically confirmed diagnosis of peripheral T-cell lymphoma, is one of the following subtypes (1) Peripheral T-cell lymphoma non-specific type (PTCL-NOS) (2) Angioimmunoblastic T-cell lymphoma (AITL) (3) Anaplastic large cell lymphoma (ALCL), ALK+ (4) Anaplastic large cell lymphoma (ALCL), ALK- (5) Other subtypes of PTCL that the researcher considered to be included in the group;
- The criteria for relapsed/refractory lymphoma: Relapsed lymphoma is defined as lymphoma that relapsed after a complete response (CR) was achieved with initial chemotherapy. Refractory lymphoma is diagnosed by meeting any of the following criteria: 1) tumor reduction < 50% or disease progression after 4 cycles of standard regimens of chemotherapy; 2) CR was achieved by standard chemotherapy, but relapse occurred within six months; 3) Two or more times of recurrence after CR; 4) Relapse after hematopoietic stem cell transplantation;
- There must be at least one evaluable or measurable lesion meeting lugano2014 criteria: for lymph node lesions, the length and diameter should be > 1.5cm; For non lymph node lesions, the length and diameter should be > 1.0cm;
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2;
- Bone marrow function: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelet count (PLT) ≥75×109/L, Hemoglobin(HB)≥ 80g/L(Bone marrow invasive patient ANC≥1.0×109/L,PLT≥50×109/L,HB≥75 g/L)
- Liver and kidney function:Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) , The liver invasion≤3.0×ULN);Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN , The liver invasion≤5.0×ULN; Serum creatinine (Scr) ≤1.5× ULN
Exclusion Criteria:
The subject had previously received any of the following anti-tumor treatments:
- Those who have previously received mitoxantrone or mitoxantrone liposomes;
- Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin is more than 550 mg/m2 (1 mg doxorubicin converted from other anthracycline drugs is equivalent to 2 mg epirubicin);
- Have received anti-tumor treatment (including chemotherapy, targeted therapy, hormone therapy, taking traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received clinical trial drugs within 4 weeks before the first use of the study drugs;
- Patients who have received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days of the first medication;
- Hypersensitivity to any study drug or its components;
- Non controlled systemic diseases (such as active infection, non controlled hypertension, diabetes, etc.)
Heart function and disease meet one of the following conditions:
- Long QT c syndrome or QTc interval > 480 ms;
- Complete left bundle branch block, grade II or III atrioventricular block;
- Serious and uncontrolled arrhythmias requiring drug treatment;
- New York Heart Association grade ≥ III;
- Cardiac ejection fraction (LVEF)< 50%;
- A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
- Baseline NT-proBNP is greater than 800pg/ mL, cTnI is greater than the normal upper limit of our center, and the retest in three days which is still higher than the above range.
- Hepatitis B, Hepatitis C infection in active stage (if there is a positive hepatitis B surface antigen or core antibody, additional test HBV DNA, Hepatitis B virus DNA more than 1x103 copies /mL excluded; If HCV anti-body is positive, add test for HCV RNA, and exclude HCV RNA over 1x103 copies /mL)
- Past or current co-occurrence of other malignancies (except effectively controlled non-melanoma cutaneous basal cell carcinoma, breast/cervical carcinoma in situ, and other malignancies effectively controlled without treatment within the past five years)
- Have primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment;
- Pregnant and lactating women and patients of childbearing age who do not want to use contraception;
- Conditions that other researchers deem inappropriate to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: liposomal mitoxantrone hydrochloride
Patients with recurrent and refractory peripheral T-cell lymphoma will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with gemcitabine, dexamethasone, and cisplatin for 6 cycles (planned) (21 days per cycle).
|
Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle. Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase II Dose(RP2D)
Time Frame: 1 year
|
To identify the RP2D
|
1 year
|
Objective response rate (ORR)
Time Frame: 3 year
|
The ORR was defined as the proportion of patients who achieved CR or PR
|
3 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose limited toxicities (DLTs)
Time Frame: 1 year
|
1 year
|
maximum-tolerated dose(MTD)
Time Frame: 1 year
|
1 year
|
The incidence of AE and SAE
Time Frame: 3 year
|
3 year
|
Complete response rate (CRR)
Time Frame: 3 year
|
3 year
|
Duration of Response(DOR)
Time Frame: 3 year
|
3 year
|
progression-free survival(PFS)
Time Frame: 3 year
|
3 year
|
Overall survival(OS)
Time Frame: 3 year
|
3 year
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Gemcitabine
- Dexamethasone
- Cisplatin
- Mitoxantrone
Other Study ID Numbers
- PUMCH-NHL-014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral T-cell Lymphoma
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
OnxeoTerminatedNon-Hodgkin's Lymphoma | Cutaneous T-Cell Lymphoma | Peripheral T-Cell LymphomaUnited States, Germany, Israel, France, Thailand
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
Clinical Trials on liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
-
Institute of Hematology & Blood Diseases Hospital...CSPC Ouyi Pharmaceutical Co., Ltd.Active, not recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Federation Francophone de Cancerologie DigestiveCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active, not recruitingNasopharyngeal Carcinoma | Recurrent or MetastaticChina
-
The Cleveland ClinicNational Cancer Institute (NCI); Duke UniversityTerminatedLeukemiaUnited States
-
NCIC Clinical Trials GroupCompleted
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting